Literature DB >> 17126920

Interplay between protein synthesis and degradation in the CNS: physiological and pathological implications.

Qunxing Ding1, Valentina Cecarini, Jeffrey N Keller.   

Abstract

Compromise of the ubiquitin-proteasome system (UPS) is a potential basis for multiple physiological abnormalities and pathologies in the CNS. This could be because reduced protein turnover leads to bulk intracellular protein accumulation. However, conditions associated with compromised UPS function are also associated with impairments in protein synthesis, and impairment of UPS function is sufficient to inhibit protein synthesis. These data suggest that the toxicity of UPS inhibition need not depend on gross intracellular protein accumulation, and indicate the potential for crosstalk between the UPS and protein-synthesis pathways. In this review, we discuss evidence for interplay between the UPS and protein-synthesis machinery, and outline the implications of this crosstalk for physiological and pathological processes in the CNS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126920     DOI: 10.1016/j.tins.2006.11.003

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  23 in total

Review 1.  Oxidative damage to RNA in aging and neurodegenerative disorders.

Authors:  Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

2.  Proteasome modulates mitochondrial function during cellular senescence.

Authors:  Claudio A Torres; Viviana I Perez
Journal:  Free Radic Biol Med       Date:  2007-10-10       Impact factor: 7.376

3.  Aging and dietary restriction effects on ubiquitination, sumoylation, and the proteasome in the heart.

Authors:  Feng Li; Le Zhang; Jeffrey Craddock; Annadora J Bruce-Keller; Kalavathi Dasuri; AnhThao Nguyen; Jeffrey N Keller
Journal:  Mech Ageing Dev       Date:  2008-04-30       Impact factor: 5.432

4.  Proteasome inhibition modulates kinase activation in neural cells: relevance to ubiquitination, ribosomes, and survival.

Authors:  Le Zhang; Philip J Ebenezer; Kalavathi Dasuri; Annadora J Bruce-Keller; Ying Liu; Jeffrey N Keller
Journal:  J Neurosci Res       Date:  2009-11-01       Impact factor: 4.164

Review 5.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

6.  Amino acid analog toxicity in primary rat neuronal and astrocyte cultures: implications for protein misfolding and TDP-43 regulation.

Authors:  Kalavathi Dasuri; Philip J Ebenezer; Romina M Uranga; Elena Gavilán; Le Zhang; Sun O K Fernandez-Kim; Annadora J Bruce-Keller; Jeffrey N Keller
Journal:  J Neurosci Res       Date:  2011-05-23       Impact factor: 4.164

7.  Selective vulnerability of neurons to acute toxicity after proteasome inhibitor treatment: implications for oxidative stress and insolubility of newly synthesized proteins.

Authors:  Kalavathi Dasuri; Philip J Ebenezer; Le Zhang; Sun Ok Fernandez-Kim; Romina M Uranga; Elena Gavilán; Alessia Di Blasio; Jeffrey N Keller
Journal:  Free Radic Biol Med       Date:  2010-08-01       Impact factor: 7.376

8.  Ubiquitin C-terminal hydrolase L1 (UCH-L1) loss causes neurodegeneration by altering protein turnover in the first postnatal weeks.

Authors:  Anna T Reinicke; Karoline Laban; Marlies Sachs; Vanessa Kraus; Michael Walden; Markus Damme; Wiebke Sachs; Julia Reichelt; Michaela Schweizer; Philipp Christoph Janiesch; Kent E Duncan; Paul Saftig; Markus M Rinschen; Fabio Morellini; Catherine Meyer-Schwesinger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-28       Impact factor: 11.205

Review 9.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

10.  Sublethal RNA oxidation as a mechanism for neurodegenerative disease.

Authors:  Rudy J Castellani; Akihiko Nunomura; Raj K Rolston; Paula I Moreira; Atsushi Takeda; George Perry; Mark A Smith
Journal:  Int J Mol Sci       Date:  2008-05-20       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.